Cyxone AB (publ) (CYXO.ST)

SEK 0.02

(0.0%)

Long Term Debt Summary of Cyxone AB (publ)

  • Cyxone AB (publ)'s latest annual long term debt in 2023 was 74 Thousand SEK , down -89.74% from previous year.
  • Cyxone AB (publ)'s latest quarterly long term debt in 2024 Q2 was - SEK , down 0.0% from previous quarter.
  • Cyxone AB (publ) reported annual long term debt of 721 Thousand SEK in 2022, down 0.0% from previous year.
  • Cyxone AB (publ) reported annual long term debt of - SEK in 2021, down 0.0% from previous year.
  • Cyxone AB (publ) reported quarterly long term debt of - SEK for 2024 Q2, down 0.0% from previous quarter.
  • Cyxone AB (publ) reported quarterly long term debt of 617 Thousand SEK for 2023 Q1, down -14.42% from previous quarter.

Annual Long Term Debt Chart of Cyxone AB (publ) (2023 - 2015)

Historical Annual Long Term Debt of Cyxone AB (publ) (2023 - 2015)

Year Long Term Debt Long Term Debt Growth
2023 74 Thousand SEK -89.74%
2022 721 Thousand SEK 0.0%
2021 - SEK 0.0%
2020 - SEK 0.0%
2019 - SEK 0.0%
2018 - SEK 0.0%
2017 - SEK 0.0%
2016 - SEK 0.0%
2015 - SEK 0.0%

Peer Long Term Debt Comparison of Cyxone AB (publ)

Name Long Term Debt Long Term Debt Difference
Alzinova AB (publ) 800 Thousand SEK 90.75%
Amniotics AB (publ) - SEK -Infinity%
Asarina Pharma AB (publ) 1 Million SEK 92.6%
BioArctic AB (publ) 2.15 Million SEK 96.561%
Calliditas Therapeutics AB (publ) 939.5 Million SEK 99.992%
Genovis AB (publ.) 74.8 Million SEK 99.901%
LIDDS AB (publ) - SEK -Infinity%
Magle Chemoswed Holding AB (publ) 32.58 Million SEK 99.773%
OncoZenge AB (publ) - SEK -Infinity%
Saniona AB (publ) 65.23 Million SEK 99.887%
Simris Alg AB (publ) 90.74 Million SEK 99.918%
Vicore Pharma Holding AB (publ) - SEK -Infinity%
AcouSort AB (publ) - SEK -Infinity%
Active Biotech AB (publ) 3 Million SEK 97.533%
Camurus AB (publ) 13.61 Million SEK 99.456%
Cantargia AB (publ) - SEK -Infinity%
Scandinavian ChemoTech AB (publ) - SEK -Infinity%
Guard Therapeutics International AB (publ) - SEK -Infinity%
Mendus AB (publ) 850 Thousand SEK 91.294%
Kancera AB (publ) - SEK -Infinity%
Karolinska Development AB (publ) - SEK -Infinity%
Lipum AB (publ) 1.76 Million SEK 95.798%
Lipigon Pharmaceuticals AB (publ) - SEK -Infinity%
NextCell Pharma AB - SEK -Infinity%
Xbrane Biopharma AB (publ) 112.89 Million SEK 99.934%
Xintela AB (publ) - SEK -Infinity%
Ziccum AB (publ) 286 Thousand SEK 74.126%
Elicera Therapeutics AB (publ) - SEK -Infinity%
Modus Therapeutics Holding AB (publ) - SEK -Infinity%
Isofol Medical AB (publ) - SEK -Infinity%
Xspray Pharma AB (publ) 31.94 Million SEK 99.768%
CombiGene AB (publ) - SEK -Infinity%
Diamyd Medical AB (publ) 30.67 Million SEK 99.759%
Intervacc AB (publ) 142 Thousand SEK 47.887%
Alligator Bioscience AB (publ) 7.51 Million SEK 99.015%
Sprint Bioscience AB (publ) - SEK -Infinity%
QuiaPEG Pharmaceuticals Holding AB (publ) - SEK -Infinity%
Corline Biomedical AB - SEK -Infinity%
IRLAB Therapeutics AB (publ) 24.51 Million SEK 99.698%
Bio-Works Technologies AB (publ) - SEK -Infinity%
Aptahem AB (publ) - SEK -Infinity%
Infant Bacterial Therapeutics AB (publ) - SEK -Infinity%
Fluicell AB (publ) - SEK -Infinity%
Biovica International AB (publ) 4.29 Million SEK 98.277%
Spago Nanomedical AB (publ) - SEK -Infinity%
Abliva AB (publ) 424 Thousand SEK 82.547%
Egetis Therapeutics AB (publ) 103.4 Million SEK 99.928%
2cureX AB (publ) - SEK -Infinity%
I-Tech AB - SEK -Infinity%
Hansa Biopharma AB (publ) 844.9 Million SEK 99.991%
ExpreS2ion Biotech Holding AB (publ) 1.43 Million SEK 94.847%
Biosergen AB - SEK -Infinity%
Nanologica AB (publ) 136 Thousand SEK 45.588%
SynAct Pharma AB 58 Thousand SEK -27.586%
Annexin Pharmaceuticals AB (publ) - SEK -Infinity%
BioInvent International AB (publ) 14.53 Million SEK 99.491%
Stayble Therapeutics AB (publ) 850 Thousand SEK 91.294%
Oncopeptides AB (publ) 106.48 Million SEK 99.931%
Pila Pharma AB (publ) - SEK -Infinity%
Ascelia Pharma AB (publ) 176 Thousand SEK 57.955%
Diagonal Bio AB (publ) - SEK -Infinity%